Panelist: Dr. Peter Schnurrenberger Chief SHE (Security, Health & Environmental Protection) Officer Roche
Panelist: Gary Cohen President Health Care Without Harm
Panelist: Nazneen Rahman CEO/Founder YewMaker (executive partner of the Sustainable Medicines Partnership) and Non-executive Director AstraZeneca
Panelist: James Gregson Life Sciences and Healthcare Managing Partner Deloitte
As pharma continues its fight against COVID-19, its battle against climate change is also starting to gain pace, with many companies having now set ambitious emissions targets and declaring their intention to lower their environmental footprint over the next few decades.
To avoid these goals becoming generic claims, execution now must be equally as bold as the targets set. So, how amongst so much current disruption does pharma make this real and link emission reduction targets to their economic value and core long-term business model?
In this Reuters Events webinar in collaboration with Deloitte, join leadership from AstraZeneca, Roche, and Health Care Without Harm, as they discuss the current pharma climate sustainability landscape, what actions have been taken so far, their impact, and what else we must do now to ensure intention becomes reality.
Key learnings include:
* Everyone who signs up receives a copy of the recording of the discussion.
Don’t miss out on the latest in pharma’s efforts to fight climate change.